Alpha 2.0
Login Register
» Authors » Sahar Tavakoli Shiraji

Sahar Tavakoli Shiraji

Explore the profile of Sahar Tavakoli Shiraji including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 17
Followers 0
Related Specialties
Oncology
Dentistry
Molecular Biology
Top 10 Co-Authors
Soroush Rad
Tanaz Bahri
Maryam Barkhordar
Mohammad Vaezi
Seied Asadollah Mousavi
Hosein Kamranzadeh Fumani
Davood Babakhani
Pouyan Aminishakib
Parvaneh Farzaneh
Parisa Shafaroudi
Published In
Front Oncol
J Oral Pathol Med
Int J Hematol Oncol Stem Cell Res
Mediterr J Hematol Infect Dis
Mol Biol Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Corrigendum: Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study
Azari M, Barkhordar M, Bahri T, Rad S, Kamranzadeh Fumani H, Mousavi S, et al.
Front Oncol . 2024 May; 14:1397607. PMID: 38699637
[This corrects the article DOI: 10.3389/fonc.2024.1339605.].
2.
Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study
Azari M, Barkhordar M, Bahri T, Rad S, Kamranzadeh Fumani H, Mousavi S, et al.
Front Oncol . 2024 Mar; 14:1339605. PMID: 38454927
Introduction: Donor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor. Methods: We...
3.
Clinical Features and Risk Factors of Relapse and Mortality in Thrombotic Thrombocytopenic Purpura Patients: A Seven-Year Experience
Tavakoli Shiraji S, Rostami M, Kamranzadeh Foumani H, Mousavi S, Vaezi M, Rad S, et al.
Int J Hematol Oncol Stem Cell Res . 2023 Oct; 17(3):156-166. PMID: 37817970
: Thrombotic thrombocytopenic purpura (TTP) is associated with microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis. No comprehensive report exists on clinical characteristics and risk factors of relapse and mortality in...
4.
The effect of aflibercept and arsenic trioxide on the proliferation, migration and apoptosis of oral squamous cell carcinoma in vitro
Derakhshan S, Aminishakib P, Pirzadeh F, Rahrotaban S, Farzaneh P, Tavakoli Shiraji S, et al.
Mol Biol Rep . 2021 Apr; 48(4):3223-3235. PMID: 33929648
Aflibercept and arsenic trioxide drugs apply a cytotoxic effect on some human cancer cell lines. However, no more study has followed the effects of both drugs, especially arsenic trioxide, on...
5.
Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the COVID-19 Pandemic: An Iranian Consensus
Mousavi S, Rad S, Rostami T, Vaezi M, Kamranzadeh Fumani H, Babakhani D, et al.
Mediterr J Hematol Infect Dis . 2020 Jul; 12(1):e2020050. PMID: 32670528
No abstract available.
6.
Anti-angiogenic efficacy of aflibercept and bevacizumab in primary oral squamous cell carcinoma cells
Ganjibakhsh M, Monshizadeh R, Nasimian A, Aminishakib P, Farzaneh P, Tavakoli Shiraji S, et al.
J Oral Pathol Med . 2018 Apr; 47(6):575-582. PMID: 29672933
Background: In recent decades, anti-angiogenic treatment strategy has been well described in cancer treatment. The anti-angiogenic activity of both bevacizumab and aflibercept has been researched on 10 previously established primary...